No changes in lymphocyte muscarinic receptors and platelet monoamine oxidase-B examined as surrogate central nervous system biomarkers in a Faroese children cohort prenatally exposed to methylmercury and polychlorinated biphenyls
暂无分享,去创建一个
P. Grandjean | U. Steuerwald | P. Weihe | F. Debes | T. Coccini | L. Manzo
[1] S. Ceccatelli,et al. Human developmental neurotoxicity of methylmercury: impact of variables and risk modifiers. , 2008, Regulatory toxicology and pharmacology : RTP.
[2] S. Ceccatelli,et al. Neurodevelopmental toxicity of methylmercury: Laboratory animal data and their contribution to human risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.
[3] N. Pivac,et al. The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[4] E. Baca-García,et al. Platelet monoamine oxidase activity in obsessive-compulsive disorder , 2007, European Psychiatry.
[5] D. Kozaric-Kovacic,et al. Monoamine oxidase (MAO) intron 13 polymorphism and platelet MAO-B activity in combat-related posttraumatic stress disorder. , 2007, Journal of affective disorders.
[6] Richard M. Eglen,et al. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development , 2007, Nature Reviews Drug Discovery.
[7] M. Goldoni,et al. Perinatal co-exposure to methylmercury and PCB153 or PCB126 in rats alters the cerebral cholinergic muscarinic receptors at weaning and puberty. , 2007, Toxicology.
[8] L. Oreland,et al. Monoamine oxidases — activities, genotypes and the shaping of behaviour , 2007, Journal of Neural Transmission.
[9] S. Ceccatelli,et al. Neurobehavioural and molecular changes induced by methylmercury exposure during development , 2007, Neurotoxicity Research.
[10] N. Saunders,et al. Developmental neurotoxicity of industrial chemicals , 2007, The Lancet.
[11] L. Bierut,et al. Association of CHRM2 with IQ: Converging Evidence for a Gene Influencing Intelligence , 2007, Behavior genetics.
[12] A. Castoldi,et al. Methylmercury interaction with lymphocyte cholinergic muscarinic receptors in developing rats. , 2007, Environmental research.
[13] D. Posthuma,et al. Association between the CHRM2 gene and intelligence in a sample of 304 Dutch families , 2006, Genes, Brain and Behavior.
[14] A. Castoldi,et al. Brain monoaminergic neurotransmission parameters in weanling rats after perinatal exposure to methylmercury and 2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB153) , 2006, Brain Research.
[15] C. Guatimosim,et al. Mice Deficient for the Vesicular Acetylcholine Transporter Are Myasthenic and Have Deficits in Object and Social Recognition , 2006, Neuron.
[16] P. Grandjean,et al. Effects of developmental co-exposure to methylmercury and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB153) on cholinergic muscarinic receptors in rat brain. , 2006, Neurotoxicology.
[17] D. Mergler,et al. Relationship between platelet monoamine oxidase-B (MAO-B) activity and mercury exposure in fish consumers from the Lake St. Pierre region of Que., Canada. , 2006, Neurotoxicology.
[18] H. Chan,et al. Effects of prenatal methylmercury exposure on brain monoamine oxidase activity and neurobehaviour of rats. , 2006, Neurotoxicology and teratology.
[19] H. Chan,et al. An interspecies comparison of mercury inhibition on muscarinic acetylcholine receptor binding in the cerebral cortex and cerebellum. , 2005, Toxicology and applied pharmacology.
[20] P. Baiardi,et al. Lymphocyte muscarinic receptors and platelet monoamine oxidase-B as biomarkers of CNS function: effects of age and gender in healthy humans. , 2005, Environmental toxicology and pharmacology.
[21] E. Budtz-Jørgensen,et al. Umbilical Cord Mercury Concentration as Biomarker of Prenatal Exposure to Methylmercury , 2005, Environmental health perspectives.
[22] S. Heidemann,et al. Disruption of intraneuronal divalent cation regulation by methylmercury: are specific targets involved in altered neuronal development and cytotoxicity in methylmercury poisoning? , 2004, Neurotoxicology.
[23] R. van Reekum,et al. A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury. , 2003, The Journal of neuropsychiatry and clinical neurosciences.
[24] P. Baiardi,et al. Platelet monoamine oxidase B activity as a state marker for alcoholism: trend over time during withdrawal and influence of smoking and gender. , 2002, Alcohol and alcoholism.
[25] L. Snell,et al. Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: activity, affinity labeling, and protein measurements. , 2002, Alcoholism, clinical and experimental research.
[26] T. Durkin,et al. Differential roles for nicotinic and muscarinic cholinergic receptors in sustained visuo-spatial attention? A study using a 5-arm maze protocol in mice , 2002, Behavioural Brain Research.
[27] L. Parnetti,et al. Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: a marker of cholinergic dysfunction? , 2001, Journal of Neuroimmunology.
[28] J. Shih,et al. Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B , 2001, Brain Research Bulletin.
[29] Roberta F. White,et al. Neurobehavioral deficits associated with PCB in 7-year-old children prenatally exposed to seafood neurotoxicants. , 2001, Neurotoxicology and teratology.
[30] Y. Kaneda,et al. Platelet serotonin concentrations in medicated schizophrenic patients , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[31] D. Rice,et al. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. , 2000, Environmental health perspectives.
[32] E. Budtz-Jørgensen,et al. Maternal seafood diet, methylmercury exposure, and neonatal neurologic function. , 2000, The Journal of pediatrics.
[33] E. Hollander,et al. Decreased platelet monoamine oxidase activity in female bulimia nervosa , 2000, European Neuropsychopharmacology.
[34] N. Martin,et al. Monoamine oxidase: associations with alcohol dependence, smoking and other measures of psychopathology , 2000, Psychological Medicine.
[35] L. Prockop,et al. Low-level exposure to methylmercury modifies muscarinic cholinergic receptor binding characteristics in rat brain and lymphocytes: physiologic implications and new opportunities in biologic monitoring. , 1999, Environmental health perspectives.
[36] L. Parnetti,et al. Radioligand binding assay of M1–M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes , 1999, Journal of Neuroimmunology.
[37] N. Keiding,et al. Methylmercury exposure biomarkers as indicators of neurotoxicity in children aged 7 years. , 1999, American journal of epidemiology.
[38] J. Hodges,et al. Attention and executive deficits in Alzheimer's disease. A critical review. , 1999, Brain : a journal of neurology.
[39] R. Verkes,et al. Platelet serotonin, monoamine oxidase activity, and [3H]paroxetine binding related to impulsive suicide attempts and borderline personality disorder , 1998, Biological Psychiatry.
[40] S. Chakrabarti,et al. Modulation of monoamine oxidase activity in different brain regions and platelets following exposure of rats to methylmercury. , 1998, Neurotoxicology and teratology.
[41] Roberta F. White,et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. , 1997, Neurotoxicology and teratology.
[42] J. Jacobson,et al. Teratogen update: polychlorinated biphenyls. , 1997, Teratology.
[43] R. Minoda,et al. Muscarinic acetylcholine receptors on human lymphocytes in patients with Menière's disease. , 1996, Acta oto-laryngologica.
[44] D. Ray,et al. Biochemical markers of neurotoxicity. A review of mechanistic studies and applications. , 1996, Human & experimental toxicology.
[45] M. Schuckit,et al. Platelet monoamine oxidase activity levels in subgroups of alcoholics: Diagnostic, temporal, and clinical correlates , 1995, Biological Psychiatry.
[46] P. Rodier,et al. Vulnerable periods and processes during central nervous system development. , 1994, Environmental health perspectives.
[47] J. Richardson,et al. Chronic L-deprenyl or L-amphetamine: Equal cognitive enhancement, unequal MAO inhibition , 1994, Pharmacology Biochemistry and Behavior.
[48] J. Shih,et al. The Deduced Amino Acid Sequences of Human Platelet and Frontal Cortex Monoamine Oxidase B Are Identical , 1993, Journal of neurochemistry.
[49] Yukun Yuan,et al. Disruption by methylmercury of membrane excitability and synaptic transmission of CA1 neurons in hippocampal slices of the rat. , 1993, Toxicology and applied pharmacology.
[50] L. Costa,et al. Modulation of muscarinic receptors and acetylcholinesterase activity in lymphocytes and in brain areas following repeated organophosphate exposure in rats. , 1993, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[51] W. Bradshaw,et al. Effect of PCB and DES on rat monoamine oxidase, acetylcholinesterase, testosterone, and estradiol ontogeny , 1992, Bulletin of environmental contamination and toxicology.
[52] A. Korczyn,et al. Decreased (3H) quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette syndrome , 1992, Biological Psychiatry.
[53] J. Rabey,et al. Changes of muscarinic cholinergic binding by lymphocytes in parkinson's disease with and without dementia , 1991, Annals of neurology.
[54] J. Nurnberger,et al. Platelet MAO in subtypes of alcoholism , 1990, Biological Psychiatry.
[55] P. Riederer,et al. Platelet MAO‐B activity and the psychopathology of Parkinson's disease, senile dementia and multi‐infarct dementia , 1988, Acta psychiatrica Scandinavica.
[56] H. Meltzer,et al. Relationship of auditory hallucinations and paranoia to platelet MAO activity in schizophrenics: Sex and race interactions , 1987, Psychiatry Research.
[57] K. Tipton,et al. Human platelet monoamine oxidase—A useful enzyme in the study of psychiatric disorders? , 1982, Neuroscience.
[58] M. Reveley,et al. Human platelet monoamine oxidase activity in health and disease: a review. , 1981, Journal of clinical pathology.
[59] D. Murphy,et al. Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. , 1977, Biochemical pharmacology.
[60] D. Murphy,et al. Reduced Monoamine Oxidase Activity in Platelets: A Possible Genetic Marker for Vulnerability to Schizophrenia , 1973, Science.
[61] D. Murphy,et al. Reduced Monoamine Oxidase Activity in Blood Platelets from Schizophrenic Patients , 1972, Nature.
[62] C. Fahlke,et al. Platelet monoamine oxidase B (MAO-B) activity and its relationship to DL-fenfluramine-induced prolactin response in healthy men , 2005, Journal of Neural Transmission.
[63] P. Riederer,et al. Monoamine oxidase-B inhibition in Alzheimer's disease. , 2004, Neurotoxicology.
[64] P. Stewart,et al. Cognitive development in preschool children prenatally exposed to PCBs and MeHg. , 2003, Neurotoxicology and teratology.
[65] L. Prockop,et al. Assessing effects of neurotoxic pollutants by biochemical markers. , 2001, Environmental research.
[66] C. Blanco,et al. Pathological gambling and platelet MAO activity: a psychobiological study. , 1996, The American journal of psychiatry.
[67] L. Costa,et al. Interaction of mercury compounds with muscarinic receptor subtypes in the rat brain. , 1996, Neurotoxicology.
[68] H. Checkoway,et al. Platelet monoamine oxidase B activity in workers exposed to styrene , 1994, International archives of occupational and environmental health.
[69] P. Eriksson,et al. Neonatal exposure to 3,3',4,4'-tetrachlorobiphenyl: changes in spontaneous behaviour and cholinergic muscarinic receptors in the adult mouse. , 1991, Toxicology.
[70] S. D. Murphy,et al. In vitro and in vivo modulation of cholinergic muscarinic receptors in rat lymphocytes and brain by cholinergic agents. , 1990, International journal of immunopharmacology.